Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Launched by MANHATTAN EYE, EAR & THROAT HOSPITAL · Sep 13, 2005

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical diagnosis of patients with diabetic retinopathy.
• • 2. Patients must be at least 18 years of age.
• • 3. Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart
• • 4. Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart
• Exclusion Criteria:
• • 1. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
• • 2. Patients who have undergone intraocular surgery within the last 2 months.
• • 3. Patient participating in any other investigational drug study.
• • 4. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
• • 5. Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access).
• • 6. Patient with significant liver disease or uremia.
• • 7. Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
• • 8. Patient has a history of any medical condition which would preclude scheduled visits or completion of study
• • 9. Patient has had insertion of scleral buckle in the study eye
• • 10. Patient has received radiation treatment
• • 11. Patient is on anticoagulant therapy with the exception of aspirin
• • 12. Patient is pregnant or nursing.

Trial Officials